# Safety and Efficacy of a Drug Delivery System in Glaucoma

> **NCT01016691** · PHASE2 · COMPLETED · sponsor: **Vistakon Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** High Dose Drug Device
- **DRUG:** Low Dose Drug Device
- **DRUG:** Placebo Device
- **DRUG:** bimatoprost 0.03%

## Key facts

- **NCT ID:** NCT01016691
- **Lead sponsor:** Vistakon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-02
- **Final completion:** —
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01016691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01016691, "Safety and Efficacy of a Drug Delivery System in Glaucoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01016691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*